Monopar Therapeutics Inc. Reports Financial Results for the Second Quarter of 2023
Net Loss and Revenue Figures Highlight Monopar's Financial Performance
Monopar Therapeutics Inc.(MNPR), a leading biopharmaceutical com pany focused on the development of innovative therapies for serious diseases, has released its condensed consolidated financial results for the second quarter of 2023. The financial data reveals both the net loss incurred by the company and the revenue generated during this period, shedding light on Monopar's financial performance.
Net Loss and Revenue Overview
Monopar reported a net loss of $2,199,991 for the three months ended June 30, 2023, which represents a reduction from the net loss of $2,762,931 reported for the same period in the previous year. Over the six months ended June 30, 2023, the company's net loss amounted to $4,634,547, marking a decrease compared to the net loss of $5,219,653 recorded during the same period in 2022.
Revenue and Operating Expenses
